Doxycycline

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, U.S. FDA, Conference, Growth, Journey, Agreement, FY, IGA, Microbiota, Risk, New Drug Application, Patient, Food and Drug Administration, Rosacea, Hyperhidrosis, NDA, Red, News, Adjustment, Dermatology, Clinical trial, Erythema, Doxycycline, Safety, GAAP, Food, Marketing, FDA, CEA, Total, PDUFA, Pharmaceutical industry

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points: 
  • ET to discuss the financial results and provide a business update
    SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
  • In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
  • In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Combination Antibiotic Therapies May Be Capable of Eradicating Lyme Disease, According to Investigational Study Funded by Bay Area Lyme Foundation

Retrieved on: 
Tuesday, November 21, 2023
Tulane University, Infection, Clofazimine, Cefotaxime, Research, FDA, Dapsone, Chronic pain, Fatigue, Lyme disease, Carbomycin, Borrelia burgdorferi, Patient, Bacteria, Doxycycline, Loratadine, Ceftriaxone, DSM-IV codes, Frontiers

These combination therapies were able to eradicate the bacteria from tissue samples, and the study was conducted by Bay Area Lyme Foundation Scientific Advisory Board member Monica Embers Ph.D. , along with other researchers from Tulane University.

Key Points: 
  • These combination therapies were able to eradicate the bacteria from tissue samples, and the study was conducted by Bay Area Lyme Foundation Scientific Advisory Board member Monica Embers Ph.D. , along with other researchers from Tulane University.
  • While none of the single courses of antibiotics eliminated persistent infection in this investigational study, some combinations of already FDA-approved antimicrobial treatments were able to eradicate the bacteria.
  • Previous studies funded by Bay Area Lyme Foundation also found other compounds, including natural botanicals, to show promise in killing Borrelia burgdorferi and superiority over commonly prescribed antibiotics in laboratory research.
  • This study was made possible by Bay Area Lyme Foundation’s science research grant program, which includes support from Project Lyme .

Petzey Addresses Unidentified Respiratory Illness Spreading Amongst Dogs

Retrieved on: 
Wednesday, December 13, 2023
Family, Health, Consumer, Infectious Diseases, Pets, Veterinary, Pet, Immune system, Pneumonia, Infection, Azithromycin, Chloramphenicol, Risk, Vaccination, Bordetella, Steroid, Weakness, Dehydration, Cold, Therapy, Human, Wheeze, Parent, Somatic symptom disorder, Dog, Lethargy, Vaccine, Doxycycline

Petzey , the leading on-demand mobile pet telehealth and wellness app, is addressing the recent outbreak of an unidentified respiratory illness affecting dogs across the country, from Oregon to Florida.

Key Points: 
  • Petzey , the leading on-demand mobile pet telehealth and wellness app, is addressing the recent outbreak of an unidentified respiratory illness affecting dogs across the country, from Oregon to Florida.
  • The condition, which has yet to be officially named, presents symptoms similar to known respiratory viruses and subsequent bacterial infections.
  • The illness can progress to pneumonia, posing a severe health risk.
  • Dr. Danny Cox, Chief Veterinary Medical Officer at Petzey, states, “What we understand about this new respiratory bug is its resemblance to other respiratory viruses like last year’s canine flu, canine parainfluenza, and treatable bacterial infections such as bordetella and pneumococcal pneumonia.

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, August 8, 2023
Rosacea, EWB, Total, PPR, SG, Marketing, Food and Drug Administration, Clinical trial, NDA, GAAP, Minocycline, Research and development, Capsule, EBITDA, Patient, Standard of care, Research, Adjustment, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Video game, Pharmaceutical industry, Doxycycline

SCOTTSDALE, Ariz., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.

Key Points: 
  • ET
    SCOTTSDALE, Ariz., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “In the second quarter of 2023, our total net revenues were $17.2 million, a 41% increase from $12.2 million in the first quarter.
  • Selling, general and administrative expenses (“SG&A”) decreased by $3.0 million, or 20%, to $12.1 million for the second quarter 2023, from $15.2 million for the second quarter 2022.
  • Research and Development (“R&D”) expenses decreased by $0.8 million, or 32%, to $1.8 million for the second quarter 2023, from $2.6 million for second quarter 2022.

Using Doxy to Prevent STIs Warrants Caution

Retrieved on: 
Wednesday, July 12, 2023
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, Post-exposure prophylaxis, Gonorrhea, AHF, PEP, HIV, STI, Press release, Tetracycline, Public, Infection, Condom, NIH, Centers for Disease Control and Prevention, Doxycycline, National Institutes of Health, CDC, IG, AIDS Healthcare Foundation, Risk, Korea Disease Control and Prevention Agency, City, Vaccine, Antibiotics

“We ignore the risk of rising antibiotic resistance at great peril to global public health,” said Michael Weinstein, AHF’s president and cofounder.

Key Points: 
  • “We ignore the risk of rising antibiotic resistance at great peril to global public health,” said Michael Weinstein, AHF’s president and cofounder.
  • “We already are facing perilous drug resistance for gonorrhea treatments.
  • Condoms remain the most effective means of preventing STIs.”
    [1] National Institutes of Health.
  • To learn more about AHF, please visit our website , find us on Facebook , follow us on IG and Twitter , or subscribe to our “AHFter Hours” podcast.

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

Retrieved on: 
Tuesday, July 11, 2023
Rosacea, IGA, FDA, Minocycline, Marketing, Safety, Pharmaceutical industry, Doxycycline

SCOTTSDALE, Ariz., July 11, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced positive topline results from the two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, Minocycline Versus Oracea® in Rosacea-1 (“MVOR-1”) and Minocycline Versus Oracea in Rosacea-2 (“MVOR-2”), evaluating Minocycline Hydrochloride Modified Release Capsules, 40 mg (“DFD-29”) for the treatment of moderate-to-severe papulopustular rosacea in adults. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.
  • Subjects in the MVOR-1 and MVOR-2 Phase 3 clinical trials were randomized in a 3:3:2 ratio to treatment with DFD-29, Doxycycline Capsules, 40 mg (“Oracea”) or placebo once daily for 16 weeks.
  • The primary objective of both studies was to evaluate the safety and efficacy of DFD-29 compared to placebo for the treatment of papulopustular rosacea.
  • Both clinical trials achieved the co-primary and all secondary endpoints, which compared the efficacy of DFD-29 to Oracea and placebo for the treatment of rosacea.

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul

Retrieved on: 
Monday, July 3, 2023
PPR, Marketing, Minocycline, Patient, FDA, Rosacea, Safety, Pharmaceutical industry, Doxycycline

DFD-29 is being developed for the treatment of PPR in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • DFD-29 is being developed for the treatment of PPR in collaboration with Dr. Reddy’s Laboratories Ltd.
  • The MVOR-1 and MVOR-2 clinical trials are randomized in a 3:3:2 ratio to DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg), Oracea (Doxycycline Capsules, 40 mg) or placebo once daily for 16 weeks.
  • The primary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to placebo for the treatment of PPR.
  • The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea (Doxycycline Capsules, 40 mg).

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

Retrieved on: 
Thursday, June 29, 2023
SHIELD, Antimalarial medication, Pharmacy, Christianity in Singapore, Polypide, Infection, Trial of the century, European Journal of Pharmaceutical Sciences, Doxycycline, Bacteria, European Journal, Safety, Vaccine, Pharmaceutical industry

PETACH TIKVA, Israel, June 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new publication highlighting the potent antibacterial activity of D-PLEX100 and its potential as an effective prophylactic drug against the most prevalent bacteria causing surgical site infections (SSIs), including resistant strains. The paper, entitled, “Potent antibacterial activity in surgical wounds with local administration of D-PLEX100” was recently published in the European Journal of Pharmaceutical Sciences and can be found here.

Key Points: 
  • Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains
    PETACH TIKVA, Israel, June 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new publication highlighting the potent antibacterial activity of D-PLEX100 and its potential as an effective prophylactic drug against the most prevalent bacteria causing surgical site infections (SSIs), including resistant strains.
  • The paper, entitled, “Potent antibacterial activity in surgical wounds with local administration of D-PLEX100” was recently published in the European Journal of Pharmaceutical Sciences and can be found here .
  • “This publication highlights the tremendous potential of D-PLEX100 in addressing the persistent challenge of surgical site infections, especially in an era of increased multidrug-resistant bacteria” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer.
  • “The data showed the significant antibacterial activity of D-PLEX100 in pre-clinical and phase 2 clinical studies against a wide range of bacteria tested, including resistant ones.

Histogen Reports First Quarter 2023 Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Mouse, CA-MRSA, Emricasan, Infection, COVID-19, Caspase, Enzyme, COVID, Inflammation, Staphylococcus, Staphylococcus aureus, ABSSSI, Doxycycline, Fungal infection, Patient, Risk, SAN, Apoptosis, Immune system, USA300, Toxicology, Safety, Pharmaceutical industry, Vaccine

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the first quarter ended March 31, 2023, and provided an update on its pipeline and other corporate developments.

Key Points: 
  • Exclusive Intellectual Property License Agreement with Johns Hopkins – In April 2023, we signed an exclusive license agreement with Johns Hopkins University.
  • Steven J. Mento Ph.D. appointed President and CEO – In March 2023, Dr. Mento was appointed President and CEO.
  • First Quarter 2023 Financial Highlights: Three Months Ended March 31, 2023 and 2022
    Revenues for the three months ended March 31, 2023 and 2022, we recognized license revenue of $5 thousand and $3.8 million, respectively.
  • Research and development expenses for the three months ended March 31, 2023 and 2022 were $1.0 million and $1.9 million, respectively.

Life Biosciences Presents Groundbreaking Data at ARVO Demonstrating Restoration of Visual Function in Nonhuman Primates

Retrieved on: 
Sunday, April 23, 2023
Tissue, Glaucoma, ARVO, Human, Stroke, Eye, Ageing, Trigeminal ganglion, Doxycycline, Research, Harvard Medical School, Doctor of Philosophy, Associate, Disorder, Patient, Perg, Primate, OSK, OCT, Neuro-ophthalmology, Optic nerve, Mouse, Association for Research in Vision and Ophthalmology, NHP, Health, Virus, RNFL, Laser damage threshold, Biology, Pharmaceutical industry, Medical device, Ophthalmology, Genetics

This approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known.

Key Points: 
  • This approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known.
  • Now, with the data presented today at ARVO, the company has demonstrated restoration of visual function and increased nerve axon survival in an NHP model that mimics human NAION deficits in retinal ganglion cells.
  • Sharon Rosenzweig-Lipson, PhD, Chief Scientific Officer of Life Bio, added, “We are delighted to present this truly groundbreaking data, which further validate Life Bio’s innovative approach to cellular rejuvenation.
  • This data moves us an important step closer to the first clinical trials of how cellular rejuvenation technology could treat aging-related diseases.”